Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evercore ISI Group Downgrades Intellia Therapeutics to In-Line, Lowers Price Target to $8

Author: Benzinga Newsdesk | November 11, 2025 05:15am
Evercore ISI Group analyst Jonathan Miller downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to In-Line and lowers the price target from $17 to $8.

Posted In: NTLA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist